<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01480687</url>
  </required_header>
  <id_info>
    <org_study_id>FO-1800</org_study_id>
    <nct_id>NCT01480687</nct_id>
  </id_info>
  <brief_title>Fish Oil Supplementation and Vascular Function in Hypertensive Patients With Hypertriglyceridemia</brief_title>
  <official_title>Effects of Fish Oil Supplementation on Vascular Structure and Function in Hypertensive Patients With Hypertriglyceridemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitario Pedro Ernesto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rio de Janeiro State Research Supporting Foundation (FAPERJ)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Universitario Pedro Ernesto</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to compare the effects of ciprofibrate versus omega-3 fatty
      acid supplementation on the vascular structure and function in hypertensive patients with
      hypertriglyceridemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypertensive patients aged 40-65 years, both genders, presenting serum triglycerides levels
      higher than 150 mg/dl will be randomized into two groups. The first group will be receiving
      ciprofibrate 100mg/day and the second group will be receiving fish oil 1800mg/day. All
      patients will be evaluated with brachial flow-mediated dilation and with EndoPAT to assess
      endothelial function before and after supplementation. SPHYGMOCOR and pulse wave velocity
      (PWV) measurements will also be obtained.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2011</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Endothelial function</measure>
    <time_frame>3 months</time_frame>
    <description>Endothelial function evaluated by brachial flow-mediated dilation and by peripheral arterial tonometry.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Hypertension</condition>
  <condition>Hypertriglyceridemia</condition>
  <arm_group>
    <arm_group_label>Omega-3 fatty acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ciprofibrate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>DHA-EPA</intervention_name>
    <description>1800 mg/day</description>
    <arm_group_label>Omega-3 fatty acid</arm_group_label>
    <other_name>OMEVITS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciprofibrate</intervention_name>
    <description>100 mg/day</description>
    <arm_group_label>Ciprofibrate</arm_group_label>
    <other_name>LIPLESS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Previous diagnosis of hypertension

          -  Patients with serum triglycerides levels ≥ 150 mg/dl and &lt;500 mg/dl

          -  Patients on stable antihypertensive medication for at least 4 weeks

          -  Patients with food consumption maintained for at least 4 weeks

        Exclusion Criteria:

          -  Smoking

          -  Secondary hypertension

          -  Hormone replacement therapy

          -  Diabetes mellitus

          -  Chronic kidney disease

          -  Known coronary artery disease

          -  Previous stroke

          -  Dyslipidemia severe, with LDL cholesterol&gt; 160 mg/dL or triglycerides ≥ 500 mg/dl

          -  Use of statins or beta blockers
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marcela A Casanova, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>State University of Rio de Janeiro</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mario F Neves, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>State University of Rio de Janeiro</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wille Oigman, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>State University of Rio de Janeiro</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fernanda J Medeiros, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Federal University of the State of Rio de Janeiro</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marcela A. Casanova, MSc</last_name>
    <phone>55-21-2868-8484</phone>
    <email>cela.abreu@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mario F. Neves, MD, PhD</last_name>
    <phone>55-21-2868-8485</phone>
    <email>mariofneves@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitario Pedro Ernesto</name>
      <address>
        <city>Rio de Janeiro, RJ</city>
        <state>Rio de Janeiro</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcela A Casanova, MSc</last_name>
      <phone>55-21-2868-8484</phone>
      <email>cela.abreu@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 22, 2011</study_first_submitted>
  <study_first_submitted_qc>November 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 29, 2011</study_first_posted>
  <last_update_submitted>November 23, 2011</last_update_submitted>
  <last_update_submitted_qc>November 23, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 29, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Universitario Pedro Ernesto</investigator_affiliation>
    <investigator_full_name>Mario Fritsch Neves</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <keyword>Endothelial dysfunction</keyword>
  <keyword>Vascular stiffness</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Hypertriglyceridemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ciprofibrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

